[Current therapeutic approach to diabetes using esters of dicarboxylic mitochondrial metabolites].
In non-insulin-dependent diabetes, site-specific defects of glucose metabolism in the pancreatic B-cell may account for a preferential alteration of its secretory response to the hexose. A novel therapeutic approach could thus be based on the use of non-glucidic nutrients that would bypass the metabolic defect in the islets of diabetic subjects. In this respect, the esters of mitochondrial dicarboxylic acids, such as succinic or glutamic acid, offer the advantage of being well transported into the islet cells and, hence, of stimulating efficiently both proinsulin biosynthesis and insulin release.
Malaisse
W J
WJ
Laboratorie de Médecine expérimentale de l'Université libre de Bruxelles.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D003998:Dicarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D004952:Esters / Q000627:therapeutic use; D007328:Insulin / Q000096:biosynthesis*; D007515:Islets of Langerhans / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects
D003998:Dicarboxylic Acids; D004952:Esters; D007328:Insulin; D015221:Potassium Channels